CAM Group Holding A S Has $2,788,000 Stake in Keryx Biopharmaceuticals Inc. (KERX)
CAM Group Holding A S maintained its position in shares of Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) during the second quarter, Holdings Channel reports. The firm owned 421,110 shares of the biopharmaceutical company’s stock at the end of the second quarter. CAM Group Holding A S’s holdings in Keryx Biopharmaceuticals were worth $2,788,000 at the end of the most recent reporting period.
Several other institutional investors have also modified their holdings of the company. LMR Partners LLP acquired a new position in shares of Keryx Biopharmaceuticals during the second quarter worth approximately $125,000. Royce & Associates LP boosted its position in Keryx Biopharmaceuticals by 32.2% in the first quarter. Royce & Associates LP now owns 451,725 shares of the biopharmaceutical company’s stock worth $2,110,000 after buying an additional 110,000 shares in the last quarter. Finally, Rice Hall James & Associates LLC boosted its position in Keryx Biopharmaceuticals by 1.3% in the second quarter. Rice Hall James & Associates LLC now owns 912,830 shares of the biopharmaceutical company’s stock worth $6,043,000 after buying an additional 11,767 shares in the last quarter. 61.15% of the stock is owned by institutional investors and hedge funds.
Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) traded down 2.44% during midday trading on Wednesday, hitting $4.40. 1,335,625 shares of the stock traded hands. The firm’s market cap is $465.94 million. The company’s 50-day moving average is $4.87 and its 200 day moving average is $5.47. Keryx Biopharmaceuticals Inc. has a 12-month low of $2.80 and a 12-month high of $7.80.
Keryx Biopharmaceuticals (NASDAQ:KERX) last released its quarterly earnings data on Monday, August 1st. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by $0.14. Keryx Biopharmaceuticals had a negative return on equity of 172.04% and a negative net margin of 590.50%. The firm had revenue of $9.30 million for the quarter, compared to analyst estimates of $8.60 million. During the same quarter in the previous year, the business posted ($0.26) earnings per share. Keryx Biopharmaceuticals’s revenue for the quarter was up 272.0% on a year-over-year basis. On average, analysts anticipate that Keryx Biopharmaceuticals Inc. will post ($1.24) EPS for the current fiscal year.
A number of equities analysts recently commented on the stock. FBR & Co reaffirmed a “market perform” rating and set a $7.00 price target on shares of Keryx Biopharmaceuticals in a research note on Tuesday. Vetr raised shares of Keryx Biopharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $5.93 price target for the company in a research note on Wednesday, October 12th. Zacks Investment Research raised shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 4th. JMP Securities reaffirmed an “outperform” rating on shares of Keryx Biopharmaceuticals in a research note on Thursday, September 8th. Finally, Cowen and Company reaffirmed a “neutral” rating on shares of Keryx Biopharmaceuticals in a research note on Wednesday, August 3rd. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $8.44.
In related news, CFO Scott A. Holmes sold 4,935 shares of the firm’s stock in a transaction dated Friday, July 29th. The shares were sold at an average price of $7.36, for a total transaction of $36,321.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 3.08% of the company’s stock.
Keryx Biopharmaceuticals Company Profile
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. The Company’s product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis.
Want to see what other hedge funds are holding KERX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Keryx Biopharmaceuticals Inc. (NASDAQ:KERX).
Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.